OncoMatch/Clinical Trials/NCT07259317
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Is NCT07259317 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Relacorilant and Nab-paclitaxel for adenocarcinoma.
Treatment: Relacorilant · Nab-paclitaxel · Gemcitabine — This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic adenocarcinoma (PDAC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Biomarker criteria
Excluded: BRCA1 mutation
Excluded: BRCA2 mutation
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anticancer chemotherapy for metastatic PDAC
Exception: Treatment of PDAC with a single agent RAS inhibitor is permitted
Received no prior systemic anticancer chemotherapy to treat metastatic PDAC. Treatment of PDAC with a single agent RAS inhibitor is permitted.
Cannot have received: chemotherapy for PDAC (gemcitabine, nab-paclitaxel)
Received gemcitabine or nab-paclitaxel to treat their PDAC
Cannot have received: radiotherapy for metastatic disease
Prior treatment as follows: Radiotherapy ... for the treatment of metastatic disease
Cannot have received: surgery for metastatic disease
Prior treatment as follows: surgery ... for the treatment of metastatic disease
Cannot have received: immunotherapy for metastatic disease
Prior treatment as follows: immunotherapy ... for the treatment of metastatic disease
Cannot have received: investigational therapy for metastatic disease
Prior treatment as follows: investigational therapy ... for the treatment of metastatic disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Site 02 · Scottsdale, Arizona
- Site 04 · Los Angeles, California
- Site 12 · Orange, California
- Site 06 · Atlanta, Georgia
- Site 14 · Goshen, Indiana
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07259317 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anticancer chemotherapy for metastatic PDAC, chemotherapy for PDAC, radiotherapy for metastatic disease disqualifies patients from enrollment.
Are patients with BRCA1 alterations eligible?
No. BRCA1 mutation is an exclusion criterion.
Are patients with BRCA2 alterations eligible?
No. BRCA2 mutation is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages